Vaxart Inc (STU:NB11)
€ 0.8175 -0.02 (-2.39%) Market Cap: 186.08 Mil Enterprise Value: 146.36 Mil PE Ratio: 0 PB Ratio: 2.56 GF Score: 60/100

Q4 2022 Vaxart Inc Earnings Call Transcript

Mar 15, 2023 / 08:30PM GMT
Release Date Price: €0.7266 (+0.78%)
Operator

Greetings. Welcome to Vaxart business update and full-year 2022 financial results conference call. (Operator Instructions) Individual investors may submit written questions to [email protected]. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Brant Biehn, Senior Vice President, Business Operations. Thank you. You may begin.

Brant Biehn
Vaxart, Inc. - SVP for Business Operations

Good afternoon, and welcome to today's call. Joining us from Vaxart are Andrei Floroiu, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Science Officer; Dr. James Cummings, our Chief Medical Officer; and Phil Lee, our Chief Financial Officer.

Before we get started, I'd like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot